Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8124125 | SALIX | Solid dosage form comprising a fibrate |
Oct, 2024
(11 months from now) | |
US8481078 | SALIX | Solid dosage form comprising a fibrate |
Oct, 2024
(11 months from now) | |
US9173847 | SALIX | Tablet comprising a fibrate |
Oct, 2024
(11 months from now) | |
US7658944 | SALIX | Solid dosage form comprising a fibrate |
Dec, 2024
(1 year, 2 months from now) |
Drugs and Companies using FENOFIBRATE ingredient
Market Authorisation Date: 10 August, 2007
Treatment: For reducing total cholesterol (total-c), ldl-c, apo-lipoprotein b, or total triglycerides, and treating hypertriglyceridemia; Use of fenofibrate for reducing elevated total cholesterol (total-c), ldl...
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11529368 | SALIX | Colonoscopy—preparation |
Mar, 2032
(8 years from now) | |
US10792306 | SALIX | Colonoscopy—preparation |
Mar, 2032
(8 years from now) | |
US10780112 | SALIX | Colonoscopy-preparation |
Mar, 2032
(8 years from now) | |
US10646512 | SALIX | Colonoscopy - preparation |
Mar, 2032
(8 years from now) | |
US9592252 | SALIX | Colonoscopy—preparation |
Aug, 2032
(8 years from now) | |
US8999313 | SALIX | Compositions |
Sep, 2033
(9 years from now) | |
US10918723 | SALIX | Colon cleansing compositions and methods of use |
Sep, 2033
(9 years from now) | |
US10016504 | SALIX | Compositions |
Sep, 2033
(9 years from now) | |
US9707297 | SALIX | Compositions |
Sep, 2033
(9 years from now) | |
US9326969 | SALIX | Compositions |
Sep, 2033
(9 years from now) |
Market Authorisation Date: 04 May, 2018
Treatment: For cleansing of the colon in preparation for colonoscopy in adults
Dosage: FOR SOLUTION;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8420663 | SALIX | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(5 years from now) | |
US9492445 | SALIX | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(5 years from now) | |
US9180125 | SALIX | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(5 years from now) | |
US9724343 | SALIX | Peripheral opioid receptor antagonists and uses thereof |
Sep, 2029
(5 years from now) | |
US10307417 | SALIX | Oral formulations and lipophilic salts of methylnaltrexone |
Mar, 2031
(7 years from now) | |
US8524276 | SALIX | Oral formulations and lipophilic salts of methylnaltrexone |
Mar, 2031
(7 years from now) | |
US8956651 | SALIX | Oral formulations and lipophilic salts of methylnal trexone |
Mar, 2031
(7 years from now) | |
US10376505 | SALIX | Oral formulations and lipophilic salts of methylnaltrexone |
Mar, 2031
(7 years from now) | |
US9314461 | SALIX | Oral formulations and lipophilic salts of methylnaltrexone |
Mar, 2031
(7 years from now) |
Drugs and Companies using METHYLNALTREXONE BROMIDE ingredient
Market Authorisation Date: 19 July, 2016
Treatment: Treatment of opioid-induced constipation
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7799897 | SALIX | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
Jun, 2022
(1 year, 3 months ago) | |
US7041786 | SALIX | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
Jan, 2028
(4 years from now) | |
US10011637 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Jun, 2034
(10 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8637451 | SALIX | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
Mar, 2022
(1 year, 6 months ago) | |
US9925231 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Sep, 2031
(7 years from now) | |
US9919024 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Sep, 2031
(7 years from now) | |
US9610321 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Sep, 2031
(7 years from now) | |
US11319346 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Mar, 2032
(8 years from now) | |
US9616097 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Aug, 2032
(8 years from now) | |
US11142549 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Jun, 2034
(10 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jan 19, 2022 |
Drugs and Companies using PLECANATIDE ingredient
NCE-1 date: 2021-01-19
Market Authorisation Date: 19 January, 2017
Treatment: Elevation of intracellular cgmp resulting in increased intestinal fluid and accelerated transit; Irritable bowel syndrome with constipation; Chronic idiopathic constipation
Dosage: TABLET;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9132093 | SALIX | Controlled release and taste making oral pharmaceutical composition |
Sep, 2031
(7 years from now) | |
US8895064 | SALIX | Controlled release and taste masking oral pharmaceutical composition |
Sep, 2031
(7 years from now) | |
US9192581 | SALIX | Controlled release and taste masking oral pharmaceutical composition |
Sep, 2031
(7 years from now) | |
US10307375 | SALIX | Controlled release and taste masking oral pharmaceutical composition |
Sep, 2031
(7 years from now) | |
US10660858 | SALIX | Controlled release and taste masking oral pharmaceutical composition |
Sep, 2031
(7 years from now) |
Drugs and Companies using BUDESONIDE ingredient
Market Authorisation Date: 14 January, 2013
Treatment: Induction of remission in patients with active, mild to moderate ulcerative colitis
Dosage: TABLET, EXTENDED RELEASE;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic